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Radiotherapy clinical-trial quality assurance is a crucial yet challenging process. This 
note presents a tool that automatically extracts dose/volume statistics for determining 
dosimetry compliance review with improved efficiency and accuracy. A major objective 
of this study is to develop an automated solution for clinical-trial radiotherapy dosimetry 
review.
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InTRoDUcTIon
Quality assurance (QA) of radiation therapy (RT) procedures that include treatment-plan review is 
an important mechanism to ensure adequate dose coverage for tumor(s), while identifying risks of 
normal tissue complications (1–3). The Imaging and Radiation Oncology Core (IROC) provides RT 
QA services to the National Clinical Trial Network (NCTN). IROC services include site qualification, 
trial-design support, credentialing, data management, and case review (4–6). Case review includes 
a data-integrity review, a review of compliance with target volume and organs at risk contours by 
study chairs, and a review of dosimetry compliance (5). The dosimetry review (4, 7–11) checks 
whether the data points on planned structure dose–volume histograms (DVH) meet the protocol 
criteria. Non-compliance of target volume–dose criteria may result in treatment failure, and viola-
tion of organs at risk criteria may create complications and toxicities. It is a consensus that timely 
clinical-trial data QA is crucial for the successful RT clinical-trial management (4, 7, 8, 10, 12–15). 
A study of 174 medulloblastoma patients in 1999 found that the number of major target deviations 
in RT was strongly correlated with the risk of tumor relapse (16). Another study of 416 pancreatic 
cancer patients found that failure to adhere to protocol-specified radiation-therapy guidelines was 
associated with decreased survival (17). One published meta-analysis about radiotherapy-protocol 
deviations and clinical outcomes (18) included two lung cancer trials (19, 20), three trials for medul-
loblastoma or supratentorial primitive neuroectodermal tumors (16, 21, 22), and one trial each for 
Ewing sarcoma (23), pancreatic cancer (17), and head and neck cancer (7). The study found the 
frequency of RT QA deviations ranged from 8 to 71% (median 32%), and RT deviations were associ-
ated with a statistically significant decrease in overall survival and also secondary outcomes (18).
TABle 1 | Dosimetry-review workload of selected nRg trials (26).
Trial no. of structures 
requiring review
no. of data points 
to be reviewed
Target accrual  
for trial
HN001 17 18 758
HN002 9 14 296
GU001 3 5 185
LU001 6 14 168
BN001 13 15 576
GI001 10 16 182
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Automatic data processing is needed to improve the efficiency 
of RT QA, which at present is a crucial yet labor-intensive 
and challenging task (4). Uniformity in the data format used 
for information collection is a prerequisite of automatic data 
processing. Recently, infrastructures and guidelines were devel-
oped to improve the data uniformity within NCTN (24, 25). 
A submission-ready case should have all the structures required 
by the protocol, and the structure names should exactly follow 
the standard names as stated in each protocol (24). The dosim-
etry compliance review usually is a task of checking more than 
10-dose/volume points for agreement with stated protocol limits 
(Table 1). Considering that typically 100 or more patients are to 
be recruited per trial and there are more than 50 RT open trials 
on the NRG Oncology website (26), a tool that automatically 
extracts dose–volume points for dosimetry compliance review 
will save time, improve accuracy, and catch underlying issues with 
understanding of the protocol text. In this report, we introduce 
an automated solution that meets the need for rapid dosimetry 
review and data extraction.
MeThoDS
Workflow of the Solution
The proposed automated solution to QA for clinical-trial data 
management consists of three separate parts: (i) a standard 
syntax system that defines the plan–evaluation data points, (ii) 
an automated program with graphic user interface (GUI) writ-
ten in MATLAB, and (iii) a result output MATLAB program 
that sorts and lists the results as a spreadsheet. The combination 
of the MATLAB programs is called dose/volume point statis-
tics (DPS) (27). The workflow of this solution is illustrated in 
Figure 1. DPS takes user input (structure names and expressions 
of dose–volume points) and DVH files from DVH reviewer of 
MIM (MIM Software Inc., Cleveland, OH, USA) and automati-
cally completes computation and statistics, and then generates 
reports. The DVH files referred to in this report use the comma-
separated value format and contain more information than the 
simple DVH values (see Format of DVH File for more detailed 
information).
The GUI for DPS is shown in Figure 2. The data extraction 
requests are specified by entering the structure names and names 
of dose/volume points in DPS. The request can be exported and 
imported as a plain text file. The run button in GUI loads the 
DVH files. Details for preparing the structure names, naming of 
both dose/volume points and DVH files can be found in Sections 
“Structure Names,” “Standard Syntax System,” and “Format of 
DVH File.” For calculating the normalized dose (e.g., the ratio of 
max dose to the prescription dose), a global dose reference point 
is set. DPS allows two choices of the dose reference point: the 
prescription dose and the maximum dose. The prescription dose 
can be entered in DPS as a global parameter for all cases; however, 
the maximum dose must be from the individual DVH files. DPS 
is designed to accommodate protocols with variable prescription 
doses. A specific prescription dose value saved in the DVH file 
overwrites the globally defined prescription dose.
In operation, DPS extracts DVH data of the structure in the 
first row of GUI from the first DVH files, and it calculates values 
of the dose/volume points in the same row of GUI. Then, DPS 
moves to the next row of GUI until all dosimetry-review requests 
are processed for the case and moves on to the next case. When 
all cases are processed, DPS tabulates the dose/volume points 
for all cases in one spreadsheet report and calculates 1, 2, 5, 10, 
15, 85, 90, 95, 98, and 99% quantiles of each dose/volume point 
(Figure 3). This report can be used to evaluate the distribution of 
plan qualities for a particular protocol. Based on this information, 
it is possible to make the decision to amend a protocol to improve 
the performance of institutions’ enrollments.
Structure names
Although DPS accepts and processes any structure names defined 
by users, in order to avoid errors and confusion it is highly recom-
mended to name the structures according to the consensus of the 
NCTN structure-naming convention defined by Yu et  al. (24). 
While processing a large number of cases, maximum perfor-
mance of DPS is achievable by sorting case data by different arms 
of a protocol and running DPS separately for each arm.
Standard Syntax System
Dosimetry-review data points specified in protocols can be 
entered in DPS using a standard syntax system (Table 2). This 
syntax system intends to avoid possible confusion between abso-
lute values and relative values, as well as the inconvenience of 
using subscripts. DPS checks syntax on all the input expressions 
and reminds users of any non-acceptable expressions.
Generally, in the proposed syntax system, “D” stands for dose 
with the units (Gy or %) defined in the following pair of paren-
theses, whereas “V” stands for volume with the units (cc or %). 
Table 2 describes the syntaxes and their definitions. After setting 
the dose reference point, which is set to be 100% of the relative 
dose, the user is able to calculate percentage dose to meet special 
needs. Popular dose reference points include prescription dose 
and maximum dose. In addition, simple calculation is supported 
by the syntax system. For example, Dmean/Rx is the ratio of mean 
dose to prescription dose.
Format of DVh File
For NRG, all the RT data for submission-ready cases are saved 
in commercial software for review (MIMvista, Cleveland, OH, 
USA). The structure-dosimetry data for each case can be exported 
as a DVH file that is written in a comma-separated value format. 
These files are sometimes identified as DVH csv files. As shown in 
Figure 4, the first line (blue region) contains the patient/site ID, 
and the second line (yellow region) has structure names. Numeric 
FIgURe 2 | panel of dose/volume points statistics (DpS).
FIgURe 1 | Typical work flow of DpS tool.
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data are stored at line 3 and below, in which the first column is the 
dose data (red region), and the rest (green region) contains the 
absolute volume data of different structures.
As mentioned in Section “Workflow of the Solution,” DPS 
accommodates protocols with variable prescription dose. Case-
specific prescription dose can be saved in cell C1 of the DVH 
file (“Rx = 60 Gy,” or in short, “60”). When dose reference point 
for dosimetry review is set to be the global maximum dose, the 
maximum dose for each case needs to be saved in cell D1 of the 
DVH csv file (“Dmax = 80 Gy,” or in short, “80”), since different 
plans usually do not share the same global maximum dose.
performance of DpS
To test the performance of this tool, data extraction for dosimetry 
review of 20 DVH csv files was performed using NRG RT trial 
LU001 protocol (28). The time needed to process the task with 
DPS is recorded. As a comparison of the efficiency, the same task 
is repeated in a manual way by reading dose/volume points from 
MIMvista and typing values in a spreadsheet.
ReSUlTS
To test the performance of this tool, data extraction for dosim-
etry review of 20 DVH csv files was performed using NRG RT 
trial LU001 protocol (28). Including the time for user operation 
such as selecting DVH files, it took DPS 3 min to generate the 
final report in Excel with the computer setting as Windows 
7 Professional, Intel Xeon CPU 3.20  GHz, and 12.0  GB RAM. 
The report includes a spreadsheet for each structure as well as 
an overview spreadsheet for all the structures (Figure  3). The 
FIgURe 4 | An example DVh csv file opened in excel. The file is partially displayed.
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FIgURe 3 | Sample report spreadsheet for lU001 opened in excel. The blue region on the top shows dosimetry-review requests entered in GUI, and the 
green region contains values of dose–volume points calculated by DPS. The red region is the statistics of values in the green region. Data shown in the table are 
made examples and are not from submitted cases.
statistical results were included at the end of each spreadsheet. 
It took more than 1 h to manually extract and tabulate the same 
dose/volume points, not including the time of loading the case in 
DVH viewer of MIMvista.
DIScUSSIon
The DPS tool shows great capability of efficiency on dosim-
etry reviews by automating data extraction. The data extraction 
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TABle 2 | examples of expressions of dose/volume points and their 
definitions.
expressions Definition
D(Gy)40(cc) The dose in Gy that covers 40 cc of the structure
D(Gy)40(%) The dose in Gy that covers 40% of the structure
D(%)40(cc) The dose in percentage that covers 40 cc in the structure
D(%)40(%) The dose in percentage that covers 40% of the structure
V(cc)40(Gy) The volume in cc that is covered by a dose not <40 Gy
V(cc)40(%) The volume in cc that is covered by a dose not <40% of the 
reference dose
V(%)40(Gy) The volume in percentage that is covered by a dose not 
<40 Gy
V(%)40(%) The volume in percentage that is covered by a dose not <40% 
of reference dose
Dmax Maximum dose defined by RTOG, the same as D(Gy)0.03(cc)
Dmin Minimum dose defined by RTOG, the lowest dose for a 
point in the volume that is at least 0.03 cc in size (found on 
the DVH curve at a volume that is the total volume of the 
structure – 0.03 cc)
Dmean Mean dose in the structure
Dmean/Rx Mean dose divided by the prescription dose
Dmean/
Rx × 100
Mean dose divided by the prescription dose and multiplied  
by 100
request specifications could be exported and imported, thus 
one can perform the same analysis for future DVH csv files or 
as needed, which improves task consistency and documentation 
completeness.
The report from the DPS tool can be used to evaluate the 
distribution of plan qualities for a particular protocol. Based 
on this information, it is possible to make the decision to 
amend a protocol to improve the performance of institutions 
registering patients. In addition, DPS allows for comparing 
different ways to evaluate the dosimetry. For example, struc-
ture maximum dose can be in the formats of D(Gy)1(%)/Rx, 
D(Gy)1(%), and D(Gy)0.03(cc). One can add all the three 
formats of maximum doses to DPS, and the results in the three 
formats will be tabulated together, which is a helpful feature 
for protocol development. Furthermore, with minor revision, 
DPS may perform biomathematical NTCP and TCP model 
calculations, which will help to understand the biological 
outcomes of the cases.
conclUSIon
With the infrastructures and structure name guidelines adopted 
for clinical-trial data management (24, 25), automated tools, such 
as DPS, can greatly improve the efficiency and organization of 
clinical-trial dosimetry review.
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